{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["air pollution", "ozone", "particulate matter", "pulmonary function tests", "respiratory", "sarcoidosis", "signs and symptoms"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "29861437", "DateCompleted": {"Year": "2019", "Month": "01", "Day": "14"}, "DateRevised": {"Year": "2020", "Month": "06", "Day": "27"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2018", "Month": "05", "Day": "26"}], "ELocationID": ["1077", "10.3390/ijerph15061077"], "Journal": {"ISSN": "1660-4601", "JournalIssue": {"Volume": "15", "Issue": "6", "PubDate": {"Year": "2018", "Month": "May", "Day": "26"}}, "Title": "International journal of environmental research and public health", "ISOAbbreviation": "Int J Environ Res Public Health"}, "ArticleTitle": "Short-Term Particulate Air Pollution Exposure is Associated with Increased Severity of Respiratory and Quality of Life Symptoms in Patients with Fibrotic Sarcoidosis.", "Abstract": {"AbstractText": ["This study aimed to determine if short-term exposure to particulate matter (PM<sub>2.5</sub>) and ozone (O\u2083) is associated with increased symptoms or lung function decline in fibrotic sarcoidosis. Sixteen patients with fibrotic sarcoidosis complicated by frequent exacerbations completed pulmonary function testing and questionnaires every three months for one year. We compared 7-, 10-, and 14-day average levels of PM<sub>2.5</sub> and O\u2083 estimated at patient residences to spirometry (forced expiratory volume in 1 s (FEV1), to forced vital capacity (FVC), episodes of FEV1 decline > 10%) and questionnaire outcomes (Leicester cough questionnaire (LCQ), Saint George Respiratory Questionnaire (SGRQ), and King's Sarcoidosis Questionnaire (KSQ)) using generalized linear mixed effect models. PM<sub>2.5</sub> level averaged over 14 days was associated with lower KSQ general health status (score change -6.60 per interquartile range (IQR) PM<sub>2.5</sub> increase). PM<sub>2.5</sub> level averaged over 10 and 14 days was associated with lower KSQ lung specific health status (score change -6.93 and -6.91, respectively). PM<sub>2.5</sub> levels were not associated with FEV\u2081, FVC, episodes of FEV\u2081 decline > 10%, or respiratory symptoms measured by SGRQ or LCQ. Ozone exposure was not associated with any health outcomes. In this small cohort of patients with fibrotic sarcoidosis, PM<sub>2.5</sub> exposure was associated with increased severity of respiratory and quality of life symptoms."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA. cheryl.pirozzi@hsc.utah.edu."}], "LastName": "Pirozzi", "ForeName": "Cheryl S", "Initials": "CS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA. Daniel.Mendoza@utah.edu."}, {"Identifier": [], "Affiliation": "Department of Atmospheric Sciences, University of Utah, Salt Lake City, UT 84112, USA. Daniel.Mendoza@utah.edu."}], "LastName": "Mendoza", "ForeName": "Daniel L", "Initials": "DL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Population Health Science, University of Utah, Salt Lake City, UT 84132, USA. yizhe.xu@hsc.utah.edu."}], "LastName": "Xu", "ForeName": "Yizhe", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Divisions of Epidemiology and Public Health, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA. zhang.yue@hsc.utah.edu."}], "LastName": "Zhang", "ForeName": "Yue", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA. mary.beth.scholand@hsc.utah.edu."}], "LastName": "Scholand", "ForeName": "Mary Beth", "Initials": "MB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45219, USA. BAUGHMRP@ucmail.uc.edu."}], "LastName": "Baughman", "ForeName": "Robert P", "Initials": "RP"}], "GrantList": [{"GrantID": "UL1 TR001425", "Acronym": "TR", "Agency": "NCATS NIH HHS", "Country": "United States"}, {"GrantID": "UL1 TR002538", "Acronym": "TR", "Agency": "NCATS NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Randomized Controlled Trial", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Environ Res Public Health", "NlmUniqueID": "101238455", "ISSNLinking": "1660-4601"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Particulate Matter"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adolescent"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["analysis"], "DescriptorName": "Air Pollution"}, {"QualifierName": [], "DescriptorName": "Cohort Studies"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Linear Models"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["analysis"], "DescriptorName": "Ozone"}, {"QualifierName": ["analysis"], "DescriptorName": "Particulate Matter"}, {"QualifierName": [], "DescriptorName": "Quality of Life"}, {"QualifierName": [], "DescriptorName": "Respiratory Function Tests"}, {"QualifierName": ["epidemiology"], "DescriptorName": "Respiratory Tract Diseases"}, {"QualifierName": ["epidemiology"], "DescriptorName": "Sarcoidosis"}, {"QualifierName": [], "DescriptorName": "Severity of Illness Index"}, {"QualifierName": [], "DescriptorName": "Young Adult"}], "CoiStatement": "Dr. Baughman has received research support from Astra Zeneca, Genentech, Mallinckrodt, Gilead, and Bayer in the area of sarcoidosis treatment. Dr. Baughman has consulted for Mallinckrodt and Genentech in the area of sarcoidosis treatment. This study was approved by the Institutional Review Board of the University of Cincinnati. Individual patient consent was not required. "}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bonham C.A., Strek M.E., Patterson K.C. From granuloma to fibrosis: Sarcoidosis associated pulmonary fibrosis. Curr. Opin. Pulm. Med. 2016;22:484\u2013491. doi: 10.1097/MCP.0000000000000301.", "ArticleIdList": ["10.1097/MCP.0000000000000301", "PMC5532138", "27379967"]}, {"Citation": "Hennebicque A.-S., Nunes H., Brillet P.-Y., Moulahi H., Valeyre D., Brauner M.W. CT findings in severe thoracic sarcoidosis. Eur. Radiol. 2005;15:23\u201330. doi: 10.1007/s00330-004-2480-4.", "ArticleIdList": ["10.1007/s00330-004-2480-4", "15449010"]}, {"Citation": "Panselinas E., Judson M.A. Acute Pulmonary Exacerbations of Sarcoidosis. CHEST. 2012;142:827\u2013836. doi: 10.1378/chest.12-1060.", "ArticleIdList": ["10.1378/chest.12-1060", "23032450"]}, {"Citation": "Baughman R.P., Lower E.E. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir. Med. 2013;107:2009\u20132013. doi: 10.1016/j.rmed.2013.10.014.", "ArticleIdList": ["10.1016/j.rmed.2013.10.014", "24211131"]}, {"Citation": "Panselinas E., Judson M.A. Pulmonary Sarcoidosis. Springer; New York, NY, USA: 2014. Acute Pulmonary Exacerbation of Sarcoidosis; pp. 65\u201378."}, {"Citation": "Li J., Sun S., Tang R., Qiu H., Huang Q., Mason T.G., Tian L. Major air pollutants and risk of COPD exacerbations: A systematic review and meta-analysis. COPD. 2016;11:3079\u20133091. doi: 10.2147/COPD.S122282.", "ArticleIdList": ["10.2147/COPD.S122282", "PMC5161337", "28003742"]}, {"Citation": "Zheng X.-Y., Ding H., Jiang L.-N., Chen S.-W., Zheng J.-P., Qiu M., Zhou Y.-X., Chen Q., Guan W.-J. Association between Air Pollutants and Asthma Emergency Room Visits and Hospital Admissions in Time Series Studies: A Systematic Review and Meta-Analysis. PLoS ONE. 2015;10:e0138146. doi: 10.1371/journal.pone.0138146.", "ArticleIdList": ["10.1371/journal.pone.0138146", "PMC4575194", "26382947"]}, {"Citation": "Goeminne P.C., Kici\u0144ski M., Vermeulen F., Fierens F., De Boeck K., Nemery B., Nawrot T.S., Dupont L.J. Impact of air pollution on cystic fibrosis pulmonary exacerbations: A case-crossover analysis. CHEST. 2013;143:946\u2013954. doi: 10.1378/chest.12-1005.", "ArticleIdList": ["10.1378/chest.12-1005", "23081770"]}, {"Citation": "Baughman R.P., Birring S., Judson M.A., Culver D.A., Parambil J.G., Cordova F., Lower E.E. A Double Blind, Placebo Controlled Study of Roflumilast to Prevent Acute Events in Fibrotic Sarcoidosis. Am. J. Respir. Crit. Care Med. 2017;195:A4752."}, {"Citation": "Hunninghake G.W., Costabel U., Ando M., Baughman R., Cordier J.F., du Bois R., Eklund A., Kitaichi M., Lynch J., Rizzato G., et al. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG) Adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Volume 160. American Thoracic Society; New York, NY, USA: 1999. Statement on sarcoidosis; pp. 736\u2013755.", "ArticleIdList": ["10430755"]}, {"Citation": "Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., Crapo R., Enright P., van der Grinten C.P.M., Gustafsson P., et al. ATS/ERS Task Force Standardisation of spirometry. Eur. Respir. J. 2005;26:319\u2013338. doi: 10.1183/09031936.05.00034805.", "ArticleIdList": ["10.1183/09031936.05.00034805", "16055882"]}, {"Citation": "Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am. J. Respir. Crit. Care Med. 1999;159:179\u2013187. doi: 10.1164/ajrccm.159.1.9712108.", "ArticleIdList": ["10.1164/ajrccm.159.1.9712108", "9872837"]}, {"Citation": "Lee P.-C., Roberts J.M., Catov J.M., Talbott E.O., Ritz B. First Trimester Exposure to Ambient Air Pollution, Pregnancy Complications and Adverse Birth Outcomes in Allegheny County, PA. Matern. Child Health J. 2012;17:545\u2013555. doi: 10.1007/s10995-012-1028-5.", "ArticleIdList": ["10.1007/s10995-012-1028-5", "PMC3636771", "22544506"]}, {"Citation": "American Thoracic Society ATS statement\u2013Snowbird workshop on standardization of spirometry. Am. Rev. Respir. Dis. 1979;119:831\u2013838.", "ArticleIdList": ["453705"]}, {"Citation": "Birring S.S., Prudon B., Carr A.J., Singh S.J., Morgan M.D.L., Pavord I.D. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ) Thorax. 2003;58:339\u2013343. doi: 10.1136/thorax.58.4.339.", "ArticleIdList": ["10.1136/thorax.58.4.339", "PMC1746649", "12668799"]}, {"Citation": "Jones P.W., Quirk F.H., Baveystock C.M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George\u2019s Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992;145:1321\u20131327. doi: 10.1164/ajrccm/145.6.1321.", "ArticleIdList": ["10.1164/ajrccm/145.6.1321", "1595997"]}, {"Citation": "Patel A.S., Siegert R.J., Creamer D., Larkin G., Maher T.M., Renzoni E.A., Wells A.U., Higginson I.J., Birring S.S. The development and validation of the King\u2019s Sarcoidosis Questionnaire for the assessment of health status. Thorax. 2013;68:57\u201365. doi: 10.1136/thoraxjnl-2012-201962.", "ArticleIdList": ["10.1136/thoraxjnl-2012-201962", "23065052"]}, {"Citation": "R Development Core Team . R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2013."}, {"Citation": "Newman L.S., Rose C.S., Bresnitz E.A., Rossman M.D., Barnard J., Frederick M., Terrin M.L., Weinberger S.E., Moller D.R., McLennan G., et al. ACCESS Research Group A case control etiologic study of sarcoidosis: Environmental and occupational risk factors. Am. J. Respir. Crit. Care Med. 2004;170:1324\u20131330. doi: 10.1164/rccm.200402-249OC.", "ArticleIdList": ["10.1164/rccm.200402-249OC", "15347561"]}, {"Citation": "Izbicki G., Chavko R., Banauch G.I., Weiden M.D., Berger K.I., Aldrich T.K., Hall C., Kelly K.J., Prezant D.J. World Trade Center \u201csarcoid-like\u201d granulomatous pulmonary disease in New York City Fire Department rescue workers. CHEST. 2007;131:1414\u20131423. doi: 10.1378/chest.06-2114.", "ArticleIdList": ["10.1378/chest.06-2114", "17400664"]}, {"Citation": "Jordan H.T., Stellman S.D., Prezant D., Teirstein A., Osahan S.S., Cone J.E. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. J. Occup. Environ. Med. 2011;53:966\u2013974. doi: 10.1097/JOM.0b013e31822a3596.", "ArticleIdList": ["10.1097/JOM.0b013e31822a3596", "21860326"]}, {"Citation": "Newman K.L., Newman L.S. Occupational causes of sarcoidosis. Curr. Opin. Allergy Clin. Immunol. 2012;12:145\u2013150. doi: 10.1097/ACI.0b013e3283515173.", "ArticleIdList": ["10.1097/ACI.0b013e3283515173", "PMC4196683", "22314258"]}, {"Citation": "Ter\u010delj M., Salobir B., Harlander M., Rylander R. Fungal exposure in homes of patients with sarcoidosis-an environmental exposure study. Environ. Health. 2011;10:8. doi: 10.1186/1476-069X-10-8.", "ArticleIdList": ["10.1186/1476-069X-10-8", "PMC3036600", "21251285"]}, {"Citation": "Barnard J., Rose C., Newman L., Canner M., Martyny J., McCammon C., Bresnitz E., Rossman M., Thompson B., Rybicki B., et al. ACCESS Research Group Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS) J. Occup. Environ. Med. 2005;47:226\u2013234. doi: 10.1097/01.jom.0000155711.88781.91.", "ArticleIdList": ["10.1097/01.jom.0000155711.88781.91", "15761318"]}, {"Citation": "Deubelbeiss U., Gemperli A., Schindler C., Baty F., Brutsche M.H. Prevalence of sarcoidosis in Switzerland is associated with environmental factors. Eur. Respir. J. 2010;35:1088\u20131097. doi: 10.1183/09031936.00197808.", "ArticleIdList": ["10.1183/09031936.00197808", "19897550"]}, {"Citation": "Nishiyama O., Taniguchi H., Kondoh Y., Kimura T., Kato K., Kataoka K., Ogawa T., Watanabe F., Arizono S. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010;36:1067\u20131072. doi: 10.1183/09031936.00152609.", "ArticleIdList": ["10.1183/09031936.00152609", "20413545"]}, {"Citation": "Baughman R.P., Winget D.B., Bowen E.H., Lower E.E. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc. Diffuse Lung Dis. 1997;14:154\u2013158.", "ArticleIdList": ["9306506"]}, {"Citation": "Nardi A., Brillet P.-Y., Letoumelin P., Girard F., Brauner M., Uzunhan Y., Naccache J.-M., Valeyre D., Nunes H. Stage IV sarcoidosis: Comparison of survival with the general population and causes of death. Eur. Respir. J. 2011;38:1368\u20131373. doi: 10.1183/09031936.00187410.", "ArticleIdList": ["10.1183/09031936.00187410", "22075486"]}], "ReferenceList": []}], "History": [{"Year": "2018", "Month": "5", "Day": "4"}, {"Year": "2018", "Month": "5", "Day": "17"}, {"Year": "2018", "Month": "5", "Day": "22"}, {"Year": "2018", "Month": "6", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "6", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "1", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "6", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["29861437", "PMC6025101", "10.3390/ijerph15061077", "ijerph15061077"]}}], "PubmedBookArticle": []}